Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Clinical Trial

Montelukast Efficacy for Improvement of Adult Acute Phase Mild-Moderate Asthma Attack: A Clinical Trial Study

Author(s): Hassan Motamed, Mohammadreza Maleki Verki*, Hassan Barzegari, Siamak Shariat and Saeed Hesam

Volume 16, Issue 4, 2020

Page: [246 - 251] Pages: 6

DOI: 10.2174/1573398X17666210204164717

Price: $65

Abstract

Background: Asthma, an inflammatory disease of the respiratory tract, is one of the most frequent causes of referral to emergency departments. The aim of this study is to evaluate the efficacy of montelukast as a member of LTRAs for the improvement of pulmonary function and clinical symptoms of patients with asthma.

Methods: The study was conducted on 80 patients with acute mild- moderate asthma, divided randomly into two groups of 40 subjects. A double-blind clinical trial was conducted on asthmatic patients who encounter an acute phase asthma attack. The experimental group received two montelukast 5 mg chewable tablets at arrival, accompanied by standard mild-moderate asthma treatment consisting of oxygen and nebulization with albuterol 2.5 mg and ipratropium bromide 0.5 mg in 3 doses for 60 minutes. The control group received standard mild-moderate asthma treatment plus placebo chewable tablets at the beginning without any leukotriene inhibitors. Pulmonary function tests, hemodynamic variables and Borg Dyspnea Scale were evaluated and analyzed at 0, 30, 60, 90 and 150 minutes in both case and control groups.

Results: No significant differences were observed between the case and the control group in terms of PEFR and FEV1 measurements during the study at different time points [P > 0.05]. There were no significant differences in terms of hemodynamic variables [blood pressure, pulse and respiration rate, pressure of oxygen in arterial blood] and Borg Dyspnea Scale in both groups as well.

Conclusion: The study findings showed that the montelukast administration in mild-moderate acute asthma attack setting had no significant impact on pulmonary function tests and clinical symptoms of the studied patients rather than standard asthma treatment.

Keywords: Acute asthma attack, leukotriene inhibitors, clinical improvement, pulmonary function test, pulmonary function, Montelukast.

Graphical Abstract
[1]
Hill VL, Wood PR. Asthma epidemiology, pathophysiology, and initial evaluation. Pediatr Rev 2009; 30(9): 331-5.
[http://dx.doi.org/10.1542/pir.30-9-331] [PMID: 19726699]
[2]
Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167(4): 528-33.
[http://dx.doi.org/10.1164/rccm.200208-802OC] [PMID: 12456380]
[3]
Mohammadbeigi A, Hassanzadeh J, Mousavizadeh A. Prevalence of asthma in elementary school age children in Iran-a systematic review and meta analysis study. Pak J Biol Sci 2011; 14(19): 887-93.
[http://dx.doi.org/10.3923/pjbs.2011.887.893] [PMID: 22518932]
[4]
Kaufman G. Asthma: pathophysiology, diagnosis and management. Nurs Stand 2011; 26(5): 48-56.
[http://dx.doi.org/10.7748/ns.26.5.48.s55] [PMID: 22073746]
[5]
Kim H, Mazza J. Practical guide for allergy and immunology in Canada. Allergy Asthma Clin Immunol 2011; 3: 5.
[6]
Rai SP, Patil AP, Vardhan V, Marwah V, Pethe M, Pandey IM. Best treatment guidelines for bronchial asthma. Med J Armed Forces India 2007; 63(3): 264-8.
[http://dx.doi.org/10.1016/S0377-1237(07)80151-1] [PMID: 27408013]
[7]
Korenblat PE. The role of cysteinyl leukotriene receptor antagonists in asthma therapy. Hosp Physician 2000; 36: 50-66.
[8]
Paggiaro P, Bacci E. Montelukast in asthma: a review of its efficacy and place in therapy. Ther Adv Chronic Dis 2010; 2040622310383343.
[PMID: 23251741]
[9]
Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma 2012; 49(5): 530-4.
[http://dx.doi.org/10.3109/02770903.2012.680638] [PMID: 22551116]
[10]
Shah MB, Gohil J, Khapekar S, Dave J. Montelukast versus budesonide as a first line preventive therapy in mild persistent asthma in 2 to 18 y. Indian J Pediatr 2014; 81(7): 655-9.
[http://dx.doi.org/10.1007/s12098-013-1334-y] [PMID: 24553973]
[11]
Stelmach I, Ożarek-Hanc A, Zaczeniuk M, et al. Do children with stable asthma benefit from addition of montelukast to inhaled corticosteroids: randomized, placebo controlled trial. Pulm Pharmacol Ther 2015; 31: 42-8.
[http://dx.doi.org/10.1016/j.pupt.2015.01.004] [PMID: 25640020]
[12]
Olszowiec-Chlebna M, Majak P, Brzozowska A, Bobrowska-Korzeniowska M, Jerzynska J, Stelmach I, et al. Effect of inhaled steroid and montelukast on clinical symptoms in children with newly diagnosed asthma: A pilot study. Pediatric Allergy and Immunology 2010 Jun 1 ; 21(4p2): e687-90.
[13]
Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001; 107(3): 461-8.
[http://dx.doi.org/10.1067/mai.2001.114657] [PMID: 11240946]
[14]
Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58(3): 211-6.
[http://dx.doi.org/10.1136/thorax.58.3.211] [PMID: 12612295]
[15]
Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999; 160(6): 1862-8.
[http://dx.doi.org/10.1164/ajrccm.160.6.9803042] [PMID: 10588598]
[16]
Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110(6): 847-54.
[http://dx.doi.org/10.1067/mai.2002.129413] [PMID: 12464949]
[17]
Benninger MS, Waters H. Montelukast: Pharmacology, Safety, Tolerability and Efficacy. Clin Med Ther 2009; 1: 1253-61.
[http://dx.doi.org/10.4137/CMT.S1147]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy